Rhenman & Partners Asset Management AB Takes Position in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA

Rhenman & Partners Asset Management AB acquired a new stake in Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) during the 4th quarter, Holdings Channel.com reports. The firm acquired 100,000 shares of the company’s stock, valued at approximately $2,501,000.

Several other institutional investors and hedge funds have also made changes to their positions in CNTA. TD Waterhouse Canada Inc. purchased a new stake in shares of Centessa Pharmaceuticals in the fourth quarter valued at $25,000. Knott David M Jr purchased a new position in Centessa Pharmaceuticals during the fourth quarter worth about $100,000. Mirae Asset Global Investments Co. Ltd. lifted its position in Centessa Pharmaceuticals by 26.4% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,688 shares of the company’s stock worth $117,000 after buying an additional 979 shares during the period. DNB Asset Management AS purchased a new position in Centessa Pharmaceuticals during the third quarter worth about $218,000. Finally, Sigma Planning Corp purchased a new position in Centessa Pharmaceuticals during the fourth quarter worth about $225,000. 82.01% of the stock is currently owned by hedge funds and other institutional investors.

Centessa Pharmaceuticals Price Performance

CNTA stock opened at $39.72 on Friday. The company has a debt-to-equity ratio of 0.23, a quick ratio of 9.53 and a current ratio of 9.53. Centessa Pharmaceuticals PLC Sponsored ADR has a 1 year low of $11.77 and a 1 year high of $40.26. The firm has a market cap of $5.93 billion, a P/E ratio of -22.19 and a beta of 1.11. The stock has a 50-day simple moving average of $39.64 and a 200-day simple moving average of $30.87.

Centessa Pharmaceuticals (NASDAQ:CNTA) last posted its earnings results on Tuesday, May 5th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.14). On average, equities analysts predict that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.65 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Karen M. Anderson sold 41,076 shares of the stock in a transaction dated Thursday, March 26th. The stock was sold at an average price of $30.12, for a total value of $1,237,209.12. Following the completion of the sale, the insider owned 62,085 shares in the company, valued at approximately $1,870,000.20. This trade represents a 39.82% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold a total of 115,887 shares of company stock valued at $3,346,523 in the last ninety days. 4.09% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on CNTA. Weiss Ratings reiterated a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a research report on Monday, April 20th. Needham & Company LLC lowered Centessa Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, March 31st. Stephens lowered Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, March 31st. Lifesci Capital lowered Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, April 1st. Finally, Guggenheim lowered Centessa Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, April 2nd. Four equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $41.33.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.